论文部分内容阅读
目的:观察强肾片联合缬沙坦治疗慢性肾炎蛋白尿的临床疗效。方法:将72例肾功能正常的慢性肾炎患者随机分为缬沙坦组和强肾片联合缬沙坦组,分别检测两组治疗前后24h尿蛋白定量、血压、血肌酐。结果:治疗4个月后,联合组临床疗效总有效率(83.8%)显著高于缬沙坦组(67.93%);联合组的24h尿蛋白低于缬沙坦组,血压、血肌酐两组差异无统计学意义。免疫指标方面,联合组的免疫球蛋白IgG、IgA、补体C3及淋巴细胞亚群CD+3、CD+8、CD+4、CD+8的改善优于缬沙坦组(P<0.05)。结论:强肾片联合缬沙坦比单用缬沙坦能更有效地降低慢性肾炎患者蛋白尿,并具有免疫调节作用。
Objective: To observe the clinical efficacy of Qiangshen Tablet combined with valsartan in the treatment of chronic nephritis proteinuria. Methods: Seventy-two patients with chronic nephritis with normal renal function were randomly divided into valsartan group and Qiangshen Tablet combined with valsartan group. The urinary protein excretion, blood pressure and serum creatinine were measured 24h before and after treatment. Results: After 4 months of treatment, the total effective rate (83.8%) in the combined group was significantly higher than that in the valsartan group (67.93%). The 24 h urinary protein in the combined group was lower than that in the valsartan group, blood pressure and serum creatinine The difference was not statistically significant. In terms of the immune indexes, the immunoglobulin IgG, IgA, complement C3 and lymphocyte subsets CD + 3, CD + 8, CD + 4 and CD + 8 in the combination group were better than those in the valsartan group (P <0.05). Conclusion: Qiangshen Tablet combined with valsartan can lower the proteinuria of patients with chronic nephritis more effectively than valsartan alone and has immunomodulatory effects.